PHARMING GRP SP. ADRS (F:PHG) — Market Cap & Net Worth
Market Cap & Net Worth: PHARMING GRP SP. ADRS (PHG)
PHARMING GRP SP. ADRS (F:PHG) has a market capitalization of $762.66 Million (€652.34 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #10393 globally and #1217 in its home market, demonstrating a -4.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARMING GRP SP. ADRS's stock price €13.90 by its total outstanding shares 68514762 (68.51 Million).
PHARMING GRP SP. ADRS Market Cap History: 2021 to 2026
PHARMING GRP SP. ADRS's market capitalization history from 2021 to 2026. Data shows growth from $580.73 Million to $1.10 Billion (3.89% CAGR).
PHARMING GRP SP. ADRS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARMING GRP SP. ADRS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PHG by Market Capitalization
Companies near PHARMING GRP SP. ADRS in the global market cap rankings as of May 2, 2026.
Key companies related to PHARMING GRP SP. ADRS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PHARMING GRP SP. ADRS Historical Marketcap From 2021 to 2026
Between 2021 and today, PHARMING GRP SP. ADRS's market cap moved from $580.73 Million to $ 1.10 Billion, with a yearly change of 3.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.10 Billion | 0.00% |
| 2025 | €1.10 Billion | +50.55% |
| 2024 | €728.92 Million | -9.90% |
| 2023 | €809.02 Million | -0.98% |
| 2022 | €817.03 Million | +40.69% |
| 2021 | €580.73 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of PHARMING GRP SP. ADRS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $762.66 Million USD |
| MoneyControl | $762.66 Million USD |
| MarketWatch | $762.66 Million USD |
| marketcap.company | $762.66 Million USD |
| Reuters | $762.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more